QuantRx^® Directors & Executive Officers
Walter W. Witoshkin, Director, Chairman & Chief Executive Officer
William H. Fleming, Ph.D., Director, Secretary & Chief Scientific Officer
Arthur Hull Hayes, Jr., M.D., Director
Shalom Hirschman, M.D., Director

Walter W. Witoshkin is Chairman and Chief Executive Officer of QuantRx Biomedical Corporation. A 40-year veteran of the pharmaceutical, healthcare, and biomedical industries, Mr. Witoshkin joined QuantRx in 2005. He has held senior executive positions at leading healthcare product and pharmaceutical companies, most recently SmithKline Beecham, now GlaxoSmithKline, where he was Vice President of Business Development and Chief Financial Officer. In 1989, Mr. Witoshkin established Menley & James Laboratories, Inc., after purchasing 32 SmithKline Beecham over-the-counter pharmaceutical and toiletry product brands. Menley & James had its initial public offering in 1992. He earlier held several senior finance positions at American Cyanamid, which became American Home and then Wyeth. Mr. Witoshkin joined QuantRx from Trident Group LLC; global operational consultants to the pharmaceutical and related healthcare industries. As a founding partner of Trident Group, Mr. Witoshkin specialized in alternative sourcing for manufacturing and the acquisition of technologies and products.

William H. Fleming, Ph.D. was named Chief Scientific Officer of QuantRx in July 2005. He also serves as a Director and the Secretary of the company; a position he has held since 1994. He was the Company’s Vice President of Diagnostics from 1997 through July 2005 and Acting CEO from 2003 until May 2005. He was President and Chief Operating Officer from 1994 to 1997. Dr. Fleming was President, Chief Operating Officer and a Director of ProFem until its merger with QuantRx in June 1994. Dr. Fleming was also affiliated with Sovereign Ventures, a healthcare consulting firm, and concurrently served as Director of Corporate Development of Antivirals, Inc., a biotechnology company involved in antisense technology. Dr. Fleming is a Director of ERC, a non-profit company.

Arthur Hull Hayes, Jr., M.D. has served as a Director of QuantRx since September 2006.  Prior to QuantRx, Dr. Hayes founded and was President and Chief Operating Officer of MediScience Associates, Inc., a consulting organization that works with pharmaceutical firms, biomedical companies, and foreign governments, from 1991 to January 2006, and Clinical Professor of Medicine and Pharmacology at the Pennsylvania State University College of Medicine from 1981 to 2004. From 1986 to 1990, Dr. Hayes was President and Chief Executive Officer of E.M. Pharmaceuticals, a North American subsidiary of Germany's E. Merck AG, and from 1981 to 1983 was commissioner of the United States Food and Drug Administration.

Shalom Hirschman, M.D. has served as a Director of QuantRx since September 2005. Dr. Hirschman was Professor of Medicine, Director of the Division of Infectious Diseases and Vice Chairman of the Department of Medicine at Mt. Sinai School of Medicine and the Mount Sinai Hospital. He served nearly three decades at Mt. Sinai until his retirement, when he became CEO, President, and Chief Scientific Officer of Advanced Viral Research Corporation, from which he retired in 2004.